The Impact of Atorvastatin on Cardiac Performance for Dilated Cardiomyopathy: A Meta-analysis of Randomized Controlled Studies


  • Lin Fu, MD Department of Ultrasonic, The Affiliated Hospital of Neimogo Medical University, Neimogo, China
  • Xiaoyang Shang, MD Department of Ultrasonic, The Affiliated Hospital of Neimogo Medical University, Neimogo, China
  • Xiaoshan Zhang, MD Department of Ultrasonic, The Affiliated Hospital of Neimogo Medical University, Neimogo, China



atorvastatin, dilated cardiomyopathy, cardiac performance, randomized controlled trials


Introduction: The efficacy of atorvastatin for dilated cardiomyopathy remains controversial. We conducted a systematic review and meta-analysis to explore the influence of atorvastatin on cardiac performance for dilated cardiomyopathy.

Methods: We searched PubMed, Embase, Web of
Science, EBSCO, and Cochrane library databases through February 2019 for randomized controlled trials (RCTs) assessing the effect of atorvastatin on cardiac performance for dilated cardiomyopathy. This meta-analysis was performed using the random-effects model.

Results: Five RCTs involving 401 patients were included in the meta-analysis. Overall, compared with control groups for dilated cardiomyopathy, atorvastatin treatment resulted in a significantly positive impact on left ventricular ejection fraction (standard mean difference [SMD] = 0.58; 95% confidence interval [CI] = 0.33 to 0.84; P < .00001), 6-minute walk test (SMD = 0.79; 95% CI = 0.27 to 1.31; P = .003), N-terminal pro-brain natriuretic peptide (SMD = –0.60; 95% CI = –1.18 to –0.01; P = .04), left ventricular systolic volume (SMD = 0.41; 95% CI = 0.03 to 0.79; P = .03), low-density lipoprotein (SMD = –1.37; 95% CI = –1.92 to –0.82; P = .00001), and C-reactive protein (SMD = –0.47; 95% CI = –0.72 to –0.22; P = .0002), but showed no obvious influence on left ventricular end-diastolic volume (SMD = 0.14; 95% CI = –0.37 to 0.64; P = .59).

Conclusions: Atorvastatin treatment provides significant benefits for dilated cardiomyopathy.


Banach M, Drozdz J, Okonski P, Rysz J. Immunological aspects of the statins’ function in patients with heart failure: A report from the Annual Conference of ESC - Heart Failure 2005. Cell Mol Immunol 2005;2:433-437.

Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monitor 2009;15:MS1-MS5.

Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monitor 2009;15:MS12-23.

Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, Aronow WS, Rysz J, Banach M. Statins and dilated cardiomyopathy: Do we have enough data? Expert Opin Invest Drugs 2011;20:315-323.

Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy—5-year follow-up. Lipids Health Dis 2013;12:47.

Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006;47:338-341.

Correale M, Brunetti ND, Totaro A, Montrone D, Russo AR, Fanigliulo AM, et al. Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by tissue Doppler imaging in subjects with chronic ischemic heart failure: Results from the Daunia Heart Failure Registry. Clinics 2011;66:777-784.

Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: An updated review of the literature. Curr Cardiol Rev 2017;13:209-216.

Gurgun C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008;123:102-107.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.

Higgins J, Thomas J. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011.

Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-628.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.

Kaski JP, Elliott P, Group ESCW. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz 2007;32:446-451.

Kjaergard LL, Villumsen J, Gluud C. Reported Methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-989.

Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G. Evaluation of the pleiotropic effects of statins: A reanalysis of the randomized trial evidence using Egger regression. Arterioscler Thromb Vasc Biol 2018;38:262-265.

Liu M, Wang F, Wang Y, Jin R. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: The role of inflammation. Cardiovasc Drugs Ther 2009;23:369-376.

Maisch B, Richter A, Sandmoller A, Portig I, Pankuweit S, Network BM-HF. Inflammatory dilated cardiomyopathy (DCMI). Herz 2005;30:535-544.

Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005;32:697-701.

McNally EM, Mestroni L. Dilated cardiomyopathy: Genetic determinants and mechanisms. Circ Res 2017;121:731-748.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.

Naito R, Miyauchi K, Daida H. Racial Differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb 2017;24:19-25.

Nunes JP. Statins and the cholesterol mortality paradox. Scot Med J 2017;62:19-23.

Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017;120:229-243.

Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel TT, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008;14:140-144.

Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59:646-654.

Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017;390:400-414.

Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006;97:899-904.

Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009;41:802-811.

Yoshida T, Hayashi M. Pleiotropic effects of statins on acute kidney injury: Involvement of Kruppel-like factor 4. Clin Exp Nephrol 2017;21:175-181.



How to Cite

Fu, L., Shang, X., & Zhang, X. (2020). The Impact of Atorvastatin on Cardiac Performance for Dilated Cardiomyopathy: A Meta-analysis of Randomized Controlled Studies. The Heart Surgery Forum, 23(3), E329-E334.